Background And Aim: Clenbuterol as a β-agonist drug was investigated according to the concentration of the drug available in the bodies of goats and according to the level of sensitivity of the instruments used for detection. The objective of the current study was to determine withdrawal times after giving a therapeutic dose that resulted in safe slaughters.
Materials And Methods: Five healthy male goats with a mean body weight of 20.64 kg were treated with a single dose of 5.10 mgkg in the BW onto jugular vein. Whole blood samples of approximately 5 mL were taken in a time series at 5, 30, 60, 90, 150, 210, 270, 390, 510, 630, and 750 min. At 24 h posttreatment, all subjects were sacrificed, and 300 g samples of the liver were obtained. The plasma concentration and liver residue of the drug were observed by reverse-phase high-performance liquid chromatography.
Results: The drug reached a maximum concentration of 19.233±0.331 µg/mL at 5 min, and the elimination half-life was at 173.25 min. The limit detection was obtained at 0.053 µg/mL. A one-way analysis of variance between all goats showed that elimination of the clenbuterol in their bodies was similar (p=1.00), with a withdrawal time of 1,479.326 min and no residues in the liver (p<0.05).
Conclusion: Safe times for slaughter were determined to be at 2 days, 13 h, and 12 min as the 2 safety factor (SF) time and 3 days, 1 h, and 58 min as the 3 SF time with the liver organ free from residue.elimination half-life, new method for calculating withdrawal time, prescriptions for obtained β-agonist, residues in liver.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048073 | PMC |
http://dx.doi.org/10.14202/vetworld.2018.731-738 | DOI Listing |
BMC Health Serv Res
January 2025
School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, P.O. Box 3286, Kigali, Rwanda.
Background: Strong partnerships, community engagement, and multisectoral collaboration in the health supply chain are synergistic pillars towards achieving universal health coverage. In Rwanda, the health supply chain involves the collaboration of various stakeholders, including distributors, manufacturers, wholesalers, and customers. However, since the eruption and ending of COVID-19, there has not been any study to assess stakeholders' perspectives on the status of the benefits, challenges, and best practices of collaborative partnerships among health supply chain stakeholders in Rwanda.
View Article and Find Full Text PDFSupport Care Cancer
January 2025
Swallowing Center, Osaka University Hospital, 2-15, Yamadaoka, Suita City, Osaka, 565-0871, Japan.
Purpose: Chemoradiotherapy (CRT) for head and neck cancer (HNC) often causes dysphagia. The risk of dysphagia increases during CRT tends to become more severe after finishing CRT, and persists for a few weeks thereafter. Thus, understanding the changes in swallowing physiology during and immediately after CRT is essential.
View Article and Find Full Text PDFCurr Opin Crit Care
January 2025
Department of Critical Care Medicine.
Purpose Of Review: Neuroprognostication after acute brain injury (ABI) is complex. In this review, we examine the threats to accurate neuroprognostication, discuss strategies to mitigate the self-fulfilling prophecy, and how to approach the indeterminate prognosis.
Recent Findings: The goal of neuroprognostication is to provide a timely and accurate prediction of a patient's neurologic outcome so treatment can proceed in accordance with a patient's values and preferences.
Environ Sci Pollut Res Int
January 2025
Department of Environmental Health Sciences and Technology, Institute of Health, Jimma University, Jimma, Ethiopia.
Recycling excreta resources through resource-oriented toilet systems (ROTS) holds transformative potential, yet adoption remains limited, especially where benefits could be high. This study aims to understand constraints hindering the adoption of ROTS in one such area in Ethiopia. Based on a survey among 476 households comprising 2393 individuals, we examine the plans to use ROTS and willingness to pay for ROTS and apply structural equation modelling to analyze the drivers of these two outcomes while comparing the explanative power of the extended technology acceptance model, extended theory of planned behaviour, and their combined model.
View Article and Find Full Text PDFJapan's conditional/time-limited early approval program, initiated in 2014, aimed to advance regenerative medicine by expediting market access. However, the withdrawal of autologous skeletal myoblast sheets (Heartsheet) due to ineffectiveness raises concerns about the balance between rapid approval and scientific integrity. While the program seeks to boost innovation, it risks endorsing costly, unclear treatments under national health care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!